Literature DB >> 10417175

Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines.

C M Ausiello1, R Lande, F Urbani, A la Sala, P Stefanelli, S Salmaso, P Mastrantonio, A Cassone.   

Abstract

Cell-mediated immune (CMI) responses to Bordetella pertussis antigens (pertussis toxin [PT], pertactin [PRN], and filamentous hemagglutinin [FHA]) were assessed in 48-month-old recipients of acellular pertussis [aP] vaccines (either from Chiron-Biocine [aP-CB] or from SmithKline Beecham [aP-SB]) and compared to CMI responses to the same antigens at 7 months of age, i.e., 1 month after completion of the primary immunization cycle. None of the children enrolled in this study received any booster of pertussis vaccines or was affected by pertussis during the whole follow-up period. Overall, around 75% of 4-year-old children showed a CMI-positive response to at least one B. pertussis antigen, independently of the type of aP vaccine received, and the proportion of CMI responders were at least equal at 48 and 7 months of age. However, longitudinal examination of individual responses showed that from 20 (against PT) to 37% (against FHA) of CMI responders after primary immunization became negative at 48 months of age. This loss was more than compensated for by conversion to positive CMI responses, ranging from 36% against FHA to 69% against PRN, in other children who were CMI negative at 7 months of age. In 60 to 80% of these CMI converters, a lack of decline or even marked elevation of antibody (Ab) titers against B. pertussis antigens also occurred between 20 and 48 months of age. In particular, the frequency of seropositivity to PRN and FHA (but not to PT) was roughly three times higher in CMI converters than in nonconverters. The acquisition of CMI response to B. pertussis antigens in 48-month-old children was not associated with a greater frequency of coughing episodes lasting >/=7 days and was characterized by a prevalent type 1 cytokine profile, with high gamma interferon and low or no production of interleukin-5, reminiscent of cytokine patterns following immunization with whole-cell pertussis vaccine or natural infection. Our data imply that vaccination-induced systemic CMI may wane by 4 years of age but may be acquired or naturally boosted by symptomless or minor clinical infection by B. pertussis. This might explain, at least in part, the persistence of protection against typical pertussis in aP vaccine recipients despite a substantial waning of both Ab and CMI responses induced by the primary immunization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417175      PMCID: PMC96703     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Observer bias in acellular pertussis vaccine trials.

Authors:  S Salmaso; A E Tozzi; M L Ciofi degli Atti
Journal:  Pediatrics       Date:  1999-10       Impact factor: 7.124

2.  Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.

Authors:  E Miller; L A Ashworth; K Redhead; C Thornton; P A Waight; T Coleman
Journal:  Vaccine       Date:  1997-01       Impact factor: 3.641

3.  Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens.

Authors:  C M Ausiello; R Lande; A la Sala; F Urbani; A Cassone
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

4.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

5.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

6.  Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.

Authors:  A Cassone; C M Ausiello; F Urbani; R Lande; M Giuliano; A La Sala; A Piscitelli; S Salmaso
Journal:  Arch Pediatr Adolesc Med       Date:  1997-03

7.  Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children.

Authors:  N N Tran Minh; K Edelman; Q He; M K Viljanen; H Arvilommi; J Mertsola
Journal:  Vaccine       Date:  1998-10       Impact factor: 3.641

8.  Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity.

Authors:  K Redhead; J Watkins; A Barnard; K H Mills
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

9.  A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

Authors:  K H Mills; M Ryan; E Ryan; B P Mahon
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

10.  Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates.

Authors:  P Mastrantonio; P Stefanelli; M Giuliano; Y Herrera Rojas; M Ciofi degli Atti; A Anemona; A E Tozzi
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

View more
  32 in total

1.  Development of interleukin-12-producing capacity throughout childhood.

Authors:  John W Upham; Peter T Lee; Barbara J Holt; Tricia Heaton; Susan L Prescott; Mary J Sharp; Peter D Sly; Patrick G Holt
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Impaired gamma interferon responses against parvovirus B19 by recently infected children.

Authors:  A Corcoran; S Doyle; D Waldron; A Nicholson; B P Mahon
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens.

Authors:  E J Ryan; L Nilsson; N Kjellman; L Gothefors; K H Mills
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 4.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

5.  Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.

Authors:  Claudius U Meyer; Fred Zepp; Michael Decker; Martin Lee; Swei-Ju Chang; Joel Ward; Sandra Yoder; Hugues Bogaert; Kathryn M Edwards
Journal:  Clin Vaccine Immunol       Date:  2007-01-31

6.  Characterization of co-purified acellular pertussis vaccines.

Authors:  Yinghua Xu; Yajun Tan; Catpagavalli Asokanathan; Shumin Zhang; Dorothy Xing; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.

Authors:  Dimitri A Diavatopoulos; Kathryn Margaret Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

8.  Relationship between maternal and child cytokine responses to allergen and phytohaemagglutinin 2 years after delivery.

Authors:  A-K Larsson; C Nilsson; A Höglind; E Sverremark-Ekström; G Lilja; M Troye-Blomberg
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

9.  Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine.

Authors:  Olajumoke O Fadugba; Li Wang; Qingxia Chen; Natasha B Halasa
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

10.  A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.

Authors:  Ciaran M Skerry; Joseph P Cassidy; Karen English; Pascal Feunou-Feunou; Camille Locht; Bernard P Mahon
Journal:  Clin Vaccine Immunol       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.